Abstract
Background: FcγRIIb is the only inhibitory IgG receptor, which is divided into three subtypes of FcγRIIb1, FcγRIIb2 and FcγRIIb3. It is mainly responsible for the immune balance in vivo by cross-linking with the activated receptor to intracellular transduction inhibitory signals, and it plays an important biological role in the negative regulation of innate immunity and adaptive immunity. An abnormal expression of FcγRIIb on cells would result in autoimmune diseases, infectious diseases, and so forth.
Conclusion: FcγRIIb modulates immune responses and further treats related diseases by inhibiting the activation of B lymphocytes, monocytes, mast cells, and basophils induced by activating receptors. It can be used in biotherapeutic methods such as monoclonal antibodies, chimeric recombinant proteins, bispecific antibodies, etc. Our increased understanding of FcγRIIb function also has a foundation for further research and development of FcγRIIb, which also provides potentially farreaching therapeutic implications.
Keywords: FcγRIIb, IgG receptor, BCR, Fc receptor, biological function, ITIM.
Graphical Abstract
Protein & Peptide Letters
Title:The Unique Inhibitory IgG Receptor--FcγRIIb
Volume: 25 Issue: 11
Author(s): Zhenzhen Xu, Lipeng Liu, Zhe Cui, Kewei Bi, Nan Zhang, Yanfen Zhang*Zhongcheng Liu*
Affiliation:
- Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Baoding 071002,China
- Key Laboratory of Pharmaceutical Quality Control of Hebei Province, Baoding 071002,China
Keywords: FcγRIIb, IgG receptor, BCR, Fc receptor, biological function, ITIM.
Abstract: Background: FcγRIIb is the only inhibitory IgG receptor, which is divided into three subtypes of FcγRIIb1, FcγRIIb2 and FcγRIIb3. It is mainly responsible for the immune balance in vivo by cross-linking with the activated receptor to intracellular transduction inhibitory signals, and it plays an important biological role in the negative regulation of innate immunity and adaptive immunity. An abnormal expression of FcγRIIb on cells would result in autoimmune diseases, infectious diseases, and so forth.
Conclusion: FcγRIIb modulates immune responses and further treats related diseases by inhibiting the activation of B lymphocytes, monocytes, mast cells, and basophils induced by activating receptors. It can be used in biotherapeutic methods such as monoclonal antibodies, chimeric recombinant proteins, bispecific antibodies, etc. Our increased understanding of FcγRIIb function also has a foundation for further research and development of FcγRIIb, which also provides potentially farreaching therapeutic implications.
Export Options
About this article
Cite this article as:
Xu Zhenzhen , Liu Lipeng , Cui Zhe, Bi Kewei, Zhang Nan, Zhang Yanfen*, Liu Zhongcheng*, The Unique Inhibitory IgG Receptor--FcγRIIb, Protein & Peptide Letters 2018; 25 (11) . https://dx.doi.org/10.2174/0929866525666181026162216
DOI https://dx.doi.org/10.2174/0929866525666181026162216 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Invariant Natural Killer T Cell-Based Therapy of Autoimmune Diseases
Current Immunology Reviews (Discontinued) Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Anti-CD20 in Targeting B Lymphocytes for the Treatment of Autoimmune Diseases: Clinical Benefits and Insights into the Role of B Lymphocytes in Pathophysiology
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Parasites in Rheumatoid Arthritis: Imminent Threat or Protective Effect?
Current Rheumatology Reviews A Comparison of Biological Activity of B Lymphocyte Stimulator (BLyS) Antagonist Peptibodies and the Elucidation of Possible BLyS Binding Sites
Protein & Peptide Letters Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Treatment of Refractory Autoimmune Diseases with Ablative Immunotherapy Using Monoclonal Antibodies and / or High Dose Chemotherapy with Hematopoietic Stem Cell Support
Current Pharmaceutical Design The Prevalence of the Classical and Non-Classical Cardiovascular Risk Factors in Multiple Sclerosis Patients
CNS & Neurological Disorders - Drug Targets Impact of Hydroxyl Radical Modified-Human Serum Albumin Autoantigens in Systemic Lupus Erythematosus
Current Protein & Peptide Science Neuropeptide Receptors in Intestinal Disease: Physiology and Therapeutic Potential
Current Pharmaceutical Design Therapeutic Approach to Multiple Sclerosis by Novel Oral Drugs
Recent Patents on Inflammation & Allergy Drug Discovery Endothelial Progenitor Cells as Mediators of the Crosstalk between Vascular Repair and Immunity: Lessons from Systemic Autoimmune Diseases
Current Medicinal Chemistry Pro-inflammatory Cytokines: Cellular and Molecular Drug Targets for Glucocorticoid-induced-osteoporosis via Osteocyte
Current Drug Targets Clinical Queries Addressed in Patients with Systemic Autoimmune Diseases. Can Cardiovascular Magnetic Resonance Give the Final Solution?
Inflammation & Allergy - Drug Targets (Discontinued) Gene Therapy for Immunologic Tolerance: Using Bone Marrow-Derived Cells to Treat Autoimmunity and Hemophilia
Current Stem Cell Research & Therapy Tissue-specific Glucocorticoid Signaling May Determine the Resistance Against Glucocorticoids in Autoimmune Diseases
Current Medicinal Chemistry Targeting Interleukin-1β for Pain
CNS & Neurological Disorders - Drug Targets Polypeptide Delivery Across The Blood-Brain Barrier
Current Drug Targets - CNS & Neurological Disorders Survival Factors from Activated Accessory Cells and their Role in Triggering Autoimmune Diseases
Current Medicinal Chemistry